Two novel sub-types of multiple sclerosis (MS) have been identified, a discovery potentially paving the way for new treatments. Researchers employed artificial intelligence (AI) to assess brain scans ...
Roche's experimental drug fenebrutinib achieved significant results in a Phase III trial for primary progressive multiple sclerosis (PPMS), reducing the risk of disability progression by 12%. This ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM ...
Edinburgh researchers discover unique myelin repair process, offering hope for new multiple sclerosis (MS) treatments in the UK.
Hosted on MSN
EMB 4PM Breakthrough in fight against nerve disease that's rising in under 50s, hope for new treatment
Experts may have found a way of stopping multiple sclerosis (MS) in its tracks, promising new research suggests. Scientists are still not exactly sure of what causes the disease that affects around ...
Edinburgh researchers discover unique myelin repair process, offering hope for new multiple sclerosis (MS) treatments in the ...
10don MSN
Roche says experimental drug helped slow disability in progressive multiple sclerosis study
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...
Roche has revealed the data behind a positive phase 3 trial for its oral BTK inhibitor fenebrutinib in primary progressive ...
Monoclonal antibody DMTs, especially anti-CD20 therapies, effectively prevent relapses but have limited impact on progressive MS. Progressive MS involves compartmentalized CNS inflammation, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results